← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
PLTM
GraniteShares Platinum Trust
Valuation N/A
Financial Services Risk 55 · Elevated
Price$17.23
Model IV—
P/IV—
Limited data — see page
PLTR
Palantir Technologies Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$172.56
Model IV—
P/IV—
Market implies +45.8%/yr vs model +30.5% · above model
PLTS
Platinum Analytics Cayman Ltd
Valuation N/A
Technology Risk 36 · Moderate
Price$17.50
Model IV—
P/IV—
Market implies +22.9%/yr vs model +50.0% · below model
PLUG
PLUG POWER INC
Valuation N/A
Technology Risk 34 · Moderate
Price$2.10
Model IV—
P/IV—
Market implies +34.4%/yr vs model +9.0% · above model
PLUR
Pluri Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.18
Model IV—
P/IV—
Market implies +15.2%/yr vs model +15.0% · in line
PLUT
Plutus Financial Group Ltd
Valuation N/A
Financial Services Risk 27 · Moderate
Price$2.69
Model IV—
P/IV—
Market implies +34.6%/yr vs model +15.0% · above model
PLX
Protalix BioTherapeutics, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$2.64
Model IV—
P/IV—
Market implies +28.7%/yr vs model +8.3% · above model
PLYX
Polaryx Therapeutics, Inc.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$2.01
Model IV—
P/IV—
Limited data — see page
PMAX
Powell Max Ltd
Valuation N/A
Technology
Price$0.88
Model IV—
P/IV—
Limited data — see page
PMCB
PharmaCyte Biotech, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.45
Model IV—
P/IV—
Limited data — see page
PML
PIMCO MUNICIPAL INCOME FUND II
Valuation N/A
Unknown
Price$7.01
Model IV—
P/IV—
Limited data — see page
PMM
PUTNAM MANAGED MUNICIPAL INCOME TRUST
Valuation N/A
Unknown
Price$5.94
Model IV—
P/IV—
Limited data — see page
PMN
ProMIS Neurosciences Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$13.56
Model IV—
P/IV—
Limited data — see page
PMO
PUTNAM MUNICIPAL OPPORTUNITIES TRUST
Valuation N/A
Unknown
Price$9.76
Model IV—
P/IV—
Limited data — see page
PMTR
Perimeter Acquisition Corp. I
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.42
Model IV—
P/IV—
Limited data — see page
PMTRU
Perimeter Acquisition Corp. I
Valuation N/A
Financial Services Risk 45 · Elevated
Price$11.00
Model IV—
P/IV—
Limited data — see page
PMTRW
Perimeter Acquisition Corp. I
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.68
Model IV—
P/IV—
Limited data — see page
PMVP
PMV Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.40
Model IV—
P/IV—
Limited data — see page
PNI
PIMCO NEW YORK MUNICIPAL INCOME FUND II
Valuation N/A
Unknown
Price$6.53
Model IV—
P/IV—
Limited data — see page
POAS
PHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd
Valuation N/A
Healthcare Risk 30 · Moderate
Price$0.17
Model IV—
P/IV—
Market implies +17.2%/yr vs model +15.0% · in line
POET
POET TECHNOLOGIES INC.
Valuation N/A
Technology Risk 37 · Moderate
Price$7.95
Model IV—
P/IV—
Limited data — see page
POLE
Andretti Acquisition Corp. II
Valuation N/A
Financial Services Risk 33 · Moderate
Price$10.72
Model IV—
P/IV—
Limited data — see page
POLEU
Andretti Acquisition Corp. II
Valuation N/A
Financial Services Risk 50 · Elevated
Price$10.74
Model IV—
P/IV—
Limited data — see page
POLEW
Andretti Acquisition Corp. II
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.14
Model IV—
P/IV—
Limited data — see page
POM
POMDOCTOR Ltd
Valuation N/A
Consumer Cyclical Risk 64 · High
Price$0.71
Model IV—
P/IV—
Market implies -30.5%/yr vs model +15.0% · below model
PONO
Pono Capital Four, Inc.
Valuation N/A
Financial Services
Price$10.06
Model IV—
P/IV—
Limited data — see page
PONOR
Pono Capital Four, Inc.
Valuation N/A
Financial Services
Price$0.23
Model IV—
P/IV—
Limited data — see page
PONOU
Pono Capital Four, Inc.
Valuation N/A
Financial Services
Price$10.47
Model IV—
P/IV—
Limited data — see page
PONY
Pony AI Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$6.64
Model IV—
P/IV—
Market implies +68.7%/yr vs model +9.6% · above model
POWI
POWER INTEGRATIONS INC
Valuation N/A
Technology Risk 43 · Elevated
Price$52.28
Model IV—
P/IV—
Market implies +33.0%/yr vs model -1.9% · above model
POWW
Outdoor Holding Co
Valuation N/A
Technology Risk 44 · Elevated
Price$2.13
Model IV—
P/IV—
Market implies +77.9%/yr vs model +15.0% · above model
POWWP
Outdoor Holding Co
Valuation N/A
Technology Risk 44 · Elevated
Price$24.35
Model IV—
P/IV—
Market implies +40.9%/yr vs model +2.0% · above model
PPBT
PURPLE BIOTECH LTD.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.72
Model IV—
P/IV—
Limited data — see page
PPCB
Propanc Biopharma, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.92
Model IV—
P/IV—
Limited data — see page
PPT
PUTNAM PREMIER INCOME TRUST
Valuation N/A
Unknown
Price$3.31
Model IV—
P/IV—
Limited data — see page
PPTA
PERPETUA RESOURCES CORP.
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$23.63
Model IV—
P/IV—
Market implies +92.7%/yr vs model +5.0% · above model
PRAX
Praxis Precision Medicines, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$330.55
Model IV—
P/IV—
Market implies +87.0%/yr vs model +15.0% · above model
PRE
Prenetics Global Ltd
Valuation N/A
Healthcare Risk 29 · Moderate
Price$23.47
Model IV—
P/IV—
Limited data — see page
PRENW
Prenetics Global Ltd
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.01
Model IV—
P/IV—
Limited data — see page
PRFX
PRF Technologies Ltd.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$0.86
Model IV—
P/IV—
Market implies +59.8%/yr vs model +15.0% · above model
PRHIZ
Presurance Holdings, Inc.
Valuation N/A
Financial Services Risk 55 · Elevated
Price$20.24
Model IV—
P/IV—
Limited data — see page
PRLD
Prelude Therapeutics Inc
Valuation N/A
Healthcare Risk 40 · Elevated
Price$4.59
Model IV—
P/IV—
Market implies +64.0%/yr vs model +15.0% · above model
PRM
Perimeter Solutions, Inc.
Valuation N/A
Basic Materials Risk 49 · Elevated
Price$31.56
Model IV—
P/IV—
Market implies +29.6%/yr vs model +8.0% · above model
PRME
Prime Medicine, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.13
Model IV—
P/IV—
Market implies +88.0%/yr vs model +15.0% · above model
PROF
Profound Medical Corp.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$5.97
Model IV—
P/IV—
Market implies +37.5%/yr vs model +15.0% · above model
PROK
PROKIDNEY CORP.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.80
Model IV—
P/IV—
Limited data — see page
PROP
Prairie Operating Co.
Valuation N/A
Energy Risk 27 · Moderate
Price$0.41
Model IV—
P/IV—
Market implies +11.3%/yr vs model +4.0% · above model
PRQR
ProQR Therapeutics N.V.
Valuation N/A
Healthcare Risk 55 · Elevated
Price$1.86
Model IV—
P/IV—
Limited data — see page
PRT
PermRock Royalty Trust
Valuation N/A
Energy
Price$2.07
Model IV—
P/IV—
Limited data — see page
PRTA
PROTHENA CORP PUBLIC LTD CO
Valuation N/A
Healthcare Risk 42 · Elevated
Price$8.93
Model IV—
P/IV—
Market implies +72.8%/yr vs model +2.0% · above model
PRZO
ParaZero Technologies Ltd.
Valuation N/A
Industrials Risk 45 · Elevated
Price$0.71
Model IV—
P/IV—
Market implies +43.5%/yr vs model +9.6% · above model
PS
PERSHING SQUARE INC.
Valuation N/A
Financial Services Risk 58 · Elevated
Price$39.00
Model IV—
P/IV—
Limited data — see page
PSF
Cohen & Steers Select Preferred & Income Fund, Inc.
Valuation N/A
Unknown
Price$18.81
Model IV—
P/IV—
Limited data — see page
PSFE
Paysafe Ltd
Valuation N/A
Technology Risk 62 · High
Price$6.34
Model IV—
P/IV—
Market implies -29.1%/yr vs model +3.4% · below model
PSLV
Sprott Physical Silver Trust
Valuation N/A
Financial Services Risk 40 · Elevated
Price$20.95
Model IV—
P/IV—
Limited data — see page
PSNL
Personalis, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$16.21
Model IV—
P/IV—
Market implies +95.8%/yr vs model +2.0% · above model
PSNY
Polestar Automotive Holding UK PLC
Valuation N/A
Consumer Cyclical
Price$7.40
Model IV—
P/IV—
Limited data — see page
PSNYW
Polestar Automotive Holding UK PLC
Valuation N/A
Consumer Cyclical
Price$4.04
Model IV—
P/IV—
Limited data — see page
PSO
PEARSON PLC
Valuation N/A
Communication Services Risk 32 · Moderate
Price$15.69
Model IV—
P/IV—
Limited data — see page
PSTV
PLUS THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$3.84
Model IV—
P/IV—
Market implies +70.9%/yr vs model +15.0% · above model